Prokidney
The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.
Diabetic Kidney Disease
target
Chronic Kidney Diseases
Renal Autologous Cell Therapy (REACT)
Phase 1
A Phase 1, Open-label trial where up to 10 participants will enroll in the trial after parent REACT protocol EOS visit completion. Participants may undergo a biopsy to manufacture REACT if additional biopsy tissue is required. Participants will receive 2 REACT injections separated by 6 months. All participants will be followed for 12 months post last supplemental REACT injection.}}
Study Type : | Interventional |
Estimated Enrollment : | 10 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | A Phase 1, Open-label, Supplemental Dosing Study of Participants With Chronic Kidney Disease Previously Treated With REACT (REGEN-015) |
Actual Study Start Date : | July 11, 2023 |
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | June 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Renal Autologous Cell Therapy (REACT) Participants will receive 2 REACT injections separated by 6 months. All participants will be followed for 12 months post last supplemental REACT injection. |
Biological: Renal Autologous Cell Therapy (REACT) |
Ages Eligible for Study: | 30 Years to 80 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Boise kidney and Hypertension Institute
Boise, Idaho, United States, 83642